早发性卵巢功能不全患者血清microRNA表达谱对针刺疗效的预测价值:巢式病例对照研究

注册号:

Registration number:

ITMCTR2000004172

最近更新日期:

Date of Last Refreshed on:

2020-12-16

注册时间:

Date of Registration:

2020-12-16

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

早发性卵巢功能不全患者血清microRNA表达谱对针刺疗效的预测价值:巢式病例对照研究

Public title:

Predictive value of serum microRNA on effect of acupuncture in patients with premature ovarian insufficiency: a nested case-control study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

早发性卵巢功能不全患者血清microRNA表达谱对针刺疗效的预测价值:巢式病例对照研究

Scientific title:

Predictive value of serum microRNA on effect of acupuncture in patients with premature ovarian insufficiency: a nested case-control study

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2000041021 ; ChiMCTR2000004172

申请注册联系人:

许焕芳

研究负责人:

许焕芳

Applicant:

Huangfang Xu

Study leader:

Huangfang Xu

申请注册联系人电话:

Applicant telephone:

+86 10-64089736

研究负责人电话:

Study leader's telephone:

+86 10-64089736

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

15711082019@126.com

研究负责人电子邮件:

Study leader's E-mail:

15711082019@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市东城区东直门内南小街16号

研究负责人通讯地址:

北京市东城区东直门内南小街16号

Applicant address:

16 Dongzhimennei Nanxiao Street, Dongcheng District, Beijing, China

Study leader's address:

16 Dongzhimennei Nanxiao Street, Dongcheng District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国中医科学院针灸研究所

Applicant's institution:

Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

中科针伦(2020-12-10-1)

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

中国中医科学院针灸研究所伦理委员会

Name of the ethic committee:

Ethics Committee of Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences

伦理委员会批准日期:

Date of approved by ethic committee:

2020/12/10 0:00:00

伦理委员会联系人:

李宇清

Contact Name of the ethic committee:

Yuqing Li

伦理委员会联系地址:

北京市东城区东直门内南小街16号

Contact Address of the ethic committee:

16 Dongzhimennei Nanxiao Street, Dongcheng District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国中医科学院针灸研究所

Primary sponsor:

Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences

研究实施负责(组长)单位地址:

北京市东城区东直门内南小街16号

Primary sponsor's address:

16 Dongzhimennei Nanxiao Street, Dongcheng District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院针灸医院

具体地址:

东城区东直门内南小街16号

Institution
hospital:

Acupuncture and Moxibustion Hospital of China Academy of Chinese Medical Sciences

Address:

16 Dongzhimennei Nanxiao Street, Dongcheng District

经费或物资来源:

国家自然科学基金-青年科学基金项目(No.81904308)

Source(s) of funding:

National Natural Science Foundation of China (Grant No.81904308)

研究疾病:

早发性卵巢功能不全

研究疾病代码:

Target disease:

premature ovarian insufficiency

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

析因分组(即根据危险因素或暴露因素分组)

Factorial

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

采用巢式病例对照研究,通过高通量测序分析针刺治疗有效和无效的POI患者血清miRNA的差异表达,筛选可作为标志物的miRNA并明确其预测针刺疗效的有效界点。

Objectives of Study:

Using a nested case-control study, the differential expression of serum miRNAs will be analyzed in patients with POI who are effective and ineffective in acupuncture treatment via high-thoughout sequencing. MiRNAs that can be used as markers will be screened and the effective cut-off point for predicting acupuncture efficacy will be determined.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1)18岁≤年龄<40岁; 2)符合POI诊断标准或处于亚临床期。

Inclusion criteria

1) Aged 18-40 years; 2) Meet the diagnostic criteria of POI or in the subclinical stage of POI.

排除标准:

1)多囊卵巢综合征、高催乳素血症、高雄激素血症者、甲状腺功能减退、肾上腺皮质功能减退等内分泌疾病影响排卵者; 2)合并严重心脑血管、肝、肾、恶性肿瘤、造血系统及精神疾病者; 3)拒绝签署知情同意书。

Exclusion criteria:

1) Patients with polycystic ovary syndrome, hyperprolactinemia, hyperandrogenism, hypothyroidism, adrenocortical hypofunction and other endocrine diseases that affect ovulation; 2) Patients with severe cardiovascular and cerebrovascular diseases, nephropathy ,hepatopathy, malignant tumor, hematopoietic diseases and mental disease; 3) Patients who refused to sign informed consent.

研究实施时间:

Study execute time:

From 2021-01-01

To      2023-12-31

征募观察对象时间:

Recruiting time:

From 2020-12-21

To      2023-06-30

干预措施:

Interventions:

组别:

针刺治疗有效组vs无效组

样本量:

90

Group:

effective group vs non effective group

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

样本总量 Total sample size : 90

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院针灸医院

单位级别:

一级

Institution/hospital:

Acupuncture and Moxibustion Hospital of China Academy of Chinese Medical Sciences

Level of the institution:

Primary

测量指标:

Outcomes:

指标中文名:

临床妊娠

指标类型:

次要指标

Outcome:

clinical pregnancy

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清基础FSH、LH和E2的水平

指标类型:

次要指标

Outcome:

basal serum level of FSH, LH and E2

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

获卵数

指标类型:

次要指标

Outcome:

Numbers of retrieved oocytes

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清抗苗勒管激素水平

指标类型:

次要指标

Outcome:

AMH

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

窦卵泡计数

指标类型:

主要指标

Outcome:

AFC

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

microRNA

指标类型:

主要指标

Outcome:

microRNA

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小
Min age years
最大
Max age years

Recruiting status:

Participant age:

性别:

Gender:

女性

Female

随机方法(请说明由何人用什么方法产生随机序列):

无随机,为观察性研究

Randomization Procedure (please state who generates the random number sequence and by what method):

No randomization

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

合理请求可联系通讯作者获取

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Please contact the corresponding author for reasonable request

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用CRF表采集数据,ClinResearch临床研究数据管理系统进行数据管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF table is used to collect data and clinresearch data management system is used for data management

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统